XPO Inc
Road & Rail
XPO Inc (XPO) Stock News
The latest XPO headlines and market coverage — 3 recent stories, updated throughout the day.
- GlobeNewswire Inc.·
Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress
Menarini Group and Stemline Therapeutics announced positive Phase 3 SENTRY trial results showing that selinexor combined with ruxolitinib met the primary endpoint for spleen volume reduction (SVR35) at 49.8% versus 28% for ruxolitinib alone in myelofibrosis patients. The combination also demonstrated a promising early overall survival signal with greater than 50% reduction in death risk, though it did not meet the secondary symptom score endpoint. The safety profile was manageable with no new safety signals observed.
- Benzinga·
XPO Provides North American LTL Operating Data for May 2026
GREENWICH, Conn., June 03, 2026 (GLOBE NEWSWIRE) -- XPO (NYSE: XPO ), a leading provider of freight transportation in North America, today reported certain preliminary LTL segment operating metrics for May 2026. LTL tonnage per day increased 0.5%, as compared with May 2025, attributable to a year-over-year increase of 3.3% in shipments per day and a decrease of 2.7% in weight per shipment. Actual results for May 2026 may vary from the preliminary results reported above. About XPO XPO, Inc. (NYSE: XPO ) is a leader in asset-based less-than-truckload (LTL) freight transportation in North America. The company's customer-focused organization efficiently moves 16 billion pounds of freight per year, enabled by its proprietary technology. XPO serves 55,000 customers with 594 locations and 37,000 employees in North America and Europe, and is headquartered in Greenwich, Conn., USA. Visit xpo.com for more information, and connect with XPO on LinkedIn , Facebook , X , Instagram and YouTube . Forward-looking Statements This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. In some cases, forward-looking statements can be identified by the use of forward-looking terms such as "anticipate," "estimate," ... Full story available on Benzinga.com
- Benzinga·
MEDX HOLDINGS (MEDH) REPORTS EXCEPTIONAL Q1 2026 FINANCIALS: REVENUE SURGES, EXPANSION ON TRACK, AND CEO TO SPEAK AT HEMP BEVERAGE EXPO
Austin, Texas , May 26, 2026 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE MEDX HOLDINGS (MEDH) REPORTS EXCEPTIONAL Q1 2026 FINANCIALS: REVENUE SURGES, EXPANSION ON TRACK, AND CEO TO SPEAK AT HEMP BEVERAGE EXPO AUSTIN, Texas — May 26, 2026 — MedX Holdings, Inc. (OTC: MEDH ) (soon to be Dazed Inc., pending ticker symbol DAZE), a dynamic brands and acquisition company focused on the emerging hemp, cannabis, and hospitality industries, today announced its financial results for the first quarter ended March 31, 2026. The company is thrilled to report significant year-over-year revenue and gross profit growth, continued profitability, and major traction in its nationwide franchise expansion. Q1 2026 Financial Highlights: Accelerated Growth and Profitability The first quarter of 2026 reflects the power of MedX's strategic focus on high-margin branding, efficient operations, and calculated expansion. Key financial milestones from the Q1 2026 consolidated financial statements include: Solid Revenue Growth: Q1 2026 revenues reached $521,874, representing an impressive 52.7% increase compared to revenues of $341,711 in Q1 2025. Surging Gross Profit: Gross profit for the quarter climbed to $398,990, a 70.6% jump from the $233,793 reported in the same period last year. Sustained Profitability: The company maintained a positive bottom line, reporting a net income of $22,203 for the three months ended March 31, 2026. Expansion on Track: Bringing the "Third Place" to New Cities Following the momentum built in late 2025, ... Full story available on Benzinga.com